[Vitamin D treatment--which analogs and when?]

Area of Science:

• Nephrology
• Endocrinology
• Nutritional Science

Background:

• Chronic kidney disease (CKD) impairs the kidneys' ability to produce the active form of vitamin D, 1 alpha,25-Dihydroxy-Vitamin D.
• Reduced active vitamin D levels in CKD have widespread consequences beyond skeletal health.
• Vitamin D plays a crucial role in various physiological processes.

Purpose of the Study:

• To review the multifaceted roles of vitamin D.
• To discuss the early consideration of vitamin D substitution in CKD management.
• To compare the efficacy and application of different vitamin D analogs, specifically calcitriol and paricalcitol.

Main Methods:

• Literature review of existing studies on vitamin D metabolism and supplementation in CKD.
• Analysis of the physiological actions of vitamin D and its metabolites.
• Comparative review of clinical data on calcitriol and paricalcitol in CKD patients.

Main Results:

• CKD is strongly linked to diminished 1 alpha,25-Dihydroxy-Vitamin D production.
• The effects of vitamin D deficiency extend to multiple organ systems.
• Uncertainty persists regarding the optimal type of vitamin D substitution for CKD.

Conclusions:

• Vitamin D substitution is a key consideration in early CKD treatment.
• Further research and clinical comparison are needed to clarify the best vitamin D analog (calcitriol vs. paricalcitol) for CKD patients.
• Understanding the broad impact of vitamin D is essential for comprehensive CKD care.